泊马度胺治疗难治性慢性移植物抗宿主病的随机2期试验
6个月总缓解率为47%(95%CI 30-65),均为部分缓解,两组无差异;常见不良事件为淋巴细胞减少、感染和乏力。
要点
- 泊马度胺0.5 mg/日对晚期激素难治性cGVHD安全有效。
- 6个月总缓解率47%(95%CI 30-65),可评估者为67%(45%-84%)。
- 最常见不良事件为淋巴细胞减少、感染和乏力,高剂量组8例因不良事件减量。
核心结论
- 泊马度胺0.5 mg/日是晚期激素难治性cGVHD安全有效的治疗选择。
- 数据提示泊马度胺具有抗纤维化作用,可能与血液调节性T细胞和白细胞介素-2浓度升高相关。
研究设计与样本
- 低剂量组17例接受泊马度胺0.5 mg/日口服;高剂量组17例从0.5 mg/日起始,6周内递增至2 mg/日。
- 主要终点为6个月时根据2005年美国国立卫生研究院cGVHD反应标准评估的总缓解率。
主要发现
- 意向性分析总缓解率为47%(95%CI 30-65),均为部分缓解,两组间无差异。
- 24例可评估者6个月总缓解率为67%(95%CI 45-84%)。
关键数值与推荐
- 6个月总缓解率意向性分析为47%(95%CI 30-65),可评估者为67%(95%CI 45-84%)。
临床怎么用
- 对于激素难治性中重度cGVHD,可考虑泊马度胺0.5 mg/日治疗。
- 治疗期间需监测淋巴细胞减少、感染和乏力等不良事件。
- 高剂量递增方案(至2 mg/日)因不良事件减量较多,低剂量0.5 mg/日可能更安全。
局限性
- 高剂量组8例因不良事件减量,低剂量组1例死于细菌性肺炎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steroid-refractory chronic graft-versus-host disease (cGVHD) is a therapeutic challenge. Sclerotic skin manifestations are especially difficult to treat. We conducted a randomized phase 2 clinical trial (#NCT01688466) to determine the safety, efficacy, and preferred dose of pomalidomide in persons with moderate to severe cGVHD unresponsive to corticosteroids and/or subsequent lines of therapy. Thirty-four subjects were randomized to receive pomalidomide 0.5 mg per day orally (n = 17; low-dose cohort) or 2 mg per day at a starting dose of 0.5 mg per day increasing to 2 mg per day over 6 weeks (n = 17; high-dose cohort). The primary endpoint was overall response rate (ORR) at 6 months according to the 2005 National Institutes of Health cGVHD Response Criteria. Thirty-two patients had severe sclerotic skin and received a median of 5 (range, 2-10) previous systemic therapies. ORR was 47% (95% confidence interval, 30-65) in the intention-to-treat analyses. All were partial responses, with no difference in ORR between the cohorts. ORR was 67% (45%-84%) in the 24 evaluable subjects at 6 months. Nine had improvement in National Institutes of Health joint/fascia scores (P = .018). Median change from the baseline in body surface area involvement of skin cGVHD was -7.5% (-10% to 35%; P = .002). The most frequent adverse events were lymphopenia, infection, and fatigue. Eight subjects in the high-dose cohort had dose decreases because of adverse events. There was 1 death in the low-dose cohort from bacterial pneumonia. Our data indicate antifibrotic effects of pomalidomide and possible association with increases in concentrations of blood regulatory T-cell and interleukin-2. Pomalidomide 0.5 mg per day is a safe and effective therapy for advanced corticosteroid-refractory cGVHD.
引用
- Curtis LM, Ostojic A, Venzon DJ, et al. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood. 2021. PMID: 32976576. doi:10.1182/blood.2020006892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。